Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
OVID
OVID
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
OVID News
Ovid Therapeutics Advances KCC2 Oral Activator OV4071 Clinical Trial Plans
Dec 18 2025
Newsfilter
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer to Advance CNS Drug Development
Dec 02 2025
Globenewswire
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer to Advance CNS Drug Development
Dec 02 2025
Newsfilter
Ovid Therapeutics Appoints Petra Kaufmann as Chief Medical Officer
Dec 02 2025
NASDAQ.COM
HC Wainwright & Co. Reaffirms Buy Rating for Ovid Therapeutics and Increases Price Target to $2
Nov 24 2025
Benzinga
Alto Neuroscience Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday
Nov 17 2025
Benzinga
Ovid Therapeutics (OVID) Posts Q3 Loss, Falls Short of Revenue Projections
Nov 12 2025
NASDAQ.COM
AnaptysBio, Inc. (ANAB) Exceeds Expectations for Q3 Earnings and Revenue
Nov 05 2025
NASDAQ.COM
Ovid Therapeutics (OVID) Sees 42.98% Increase Over the Past Week: Key Insights to Consider
Oct 06 2025
NASDAQ.COM
Ovid Soars Following Encouraging Findings from Epilepsy Research
Oct 03 2025
SeekingAlpha
Ovid Therapeutics Soars 28% Following $175M Private Placement
Oct 03 2025
SeekingAlpha
ZCMD, ABCL, VOR, IXHL, OVID, BFRG Surge in After-Hours Trading Due to Clinical Progress and Recent Developments
Oct 02 2025
NASDAQ.COM
Biotech Stocks Recover in After-Hours Trading Driven by Positive Sector Trends
Oct 01 2025
NASDAQ.COM
Diverse Catalysts Influence After-Hours Activity in MRM, LEXX, SHOT, AQST, and OVID
Sep 26 2025
NASDAQ.COM
Lucid Capital Begins Coverage of Ovid Therapeutics Inc. (OVID) with a Buy Rating and $5.50 Price Target
Aug 23 2025
Yahoo Finance
Top Analysts Recommend 3 Stocks to Purchase Now, August 18, 2025
Aug 18 2025
TipRanks
Show More News
